January 22, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PDD Holdings Inc. (“PDD” or “the Company”) (NASDAQ: PDD). Investors who purchased PDD securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether PDD has violated… read more
January 20, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lantheus Holdings, Inc. (“Lantheus” or “the Company”) (NASDAQ: LNTH). Investors who purchased Lantheus securities prior to November 6, 2024, and continue to hold to the present, are encouraged to obtain additional… read more
January 20, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lineage, Inc. (“Lineage” or “the Company”) (NASDAQ: LINE). Investors who purchased Lineage securities prior to July 25, 2025, and continue to hold to the present, are encouraged to obtain additional information… read more
January 19, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Skye Bioscience, Inc. (“Skye” or “the Company”) (NASDAQ: SKYE). Investors who purchased Skye securities prior to November 4, 2024, and continue to hold to the present, are encouraged to obtain additional… read more
January 16, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Phoenix Education Partners, Inc. (“Phoenix” or “the Company”) (NYSE: PXED). Investors who purchased Phoenix securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Phoenix has… read more
January 14, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Teleflex Incorporated (“Teleflex” or “the Company”) (NYSE: TFX). Investors who purchased Teleflex securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Teleflex has violated federal… read more
January 13, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Primo Brands Corporation (“Primo Brands” or “the Company”) (NYSE: PRMB). Investors who purchased Primo Brands securities prior to November 11, 2024, and continue to hold to the present, are encouraged to… read more
January 13, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Stride, Inc. (“Stride” or “the Company”) (NYSE: LRN). Investors who purchased Stride securities prior to October 22, 2024, and continue to hold to the present, are encouraged to obtain additional information… read more
January 13, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Nutanix, Inc. (“Nutanix” or “the Company”) (NASDAQ: NTNX). Investors who purchased Nutanix securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Nutanix has violated federal… read more
January 12, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Nestlé S.A. (“Nestlé” or “the Company”) (OTCMKTS: NSRGY). Investors who purchased Nestlé securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Nestlé has violated federal… read more
January 12, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Beta Bionics, Inc. (“Beta Bionics” or “the Company”) (NASDAQ: BBNX). Investors who purchased Beta Bionics securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Beta… read more
January 9, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Synopsys, Inc. (“Synopsys” or “the Company”) (NASDAQ: SNPS). Investors who purchased Synopsys securities prior to December 4, 2024, and continue to hold to the present, are encouraged to obtain additional information… read more
January 9, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Avantor, Inc. (“Avantor” or “the Company”) (NYSE: AVTR). Investors who purchased Avantor securities prior to March 5, 2024, and continue to hold to the present, are encouraged to obtain additional information… read more
January 8, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Instil Bio, Inc. (“Instil” or “the Company”) (NASDAQ: TIL). Investors who purchased Instil securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Instil has violated… read more
January 8, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Molina Healthcare, Inc. (“Molina” or “the Company”) (NYSE: MOH). Investors who purchased Molina securities prior to February 5, 2025, and continue to hold to the present, are encouraged to obtain additional… read more
January 8, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Quanex Building Products Corporation (“Quanex” or “the Company”) (NYSE: NX). Investors who purchased Quanex securities prior to December 12, 2024, and continue to hold to the present, are encouraged to obtain… read more
January 8, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR). Investors who purchased Jasper securities prior to November 30, 2023, and continue to hold to the present, are encouraged to obtain additional… read more
January 8, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NANO Nuclear Energy Inc. (“NNE” or “the Company”) (NASDAQ: NNE). Investors who purchased NNE securities prior to May 8, 2024, and continue to hold to the present, are encouraged to obtain… read more
January 7, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zenas BioPharma, Inc. (“Zenas” or “the Company”) (NASDAQ: ZBIO). Investors who purchased Zenas securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Zenas has violated… read more
January 7, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of KBR, Inc. (“KBR” or “the Company”) (NYSE: KBR). Investors who purchased KBR securities prior to May 6, 2025, and continue to hold to the present, are encouraged to obtain additional information… read more
January 7, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytokinetics, Incorporated (“Cytokinetics” or “the Company”) (NASDAQ: CYTK). Investors who purchased Cytokinetics securities prior to December 27, 2023, and continue to hold to the present, are encouraged to obtain additional information… read more
January 7, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pacira BioSciences, Inc. (“Pacira” or “the Company”) (NASDAQ: PCRX). Investors who purchased Pacira securities prior to August 2, 2023, and continue to hold to the present, are encouraged to obtain additional… read more
January 7, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of DoubleVerify Holdings, Inc. (“DoubleVerify” or “the Company”) (NYSE: DV). Investors who purchased DoubleVerify securities prior to November 10, 2023, and continue to hold to the present, are encouraged to obtain additional… read more
January 7, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PACS Group, Inc. (“PACS” or “the Company”) (NYSE: PACS). Investors who purchased PACS securities prior to April 11, 2024, and continue to hold to the present, are encouraged to obtain additional… read more
January 7, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sun Communities, Inc. (“Sun Communities” or “the Company”) (NYSE: SUI). Investors who purchased Sun Communities securities prior to February 28, 2019, and continue to hold to the present, are encouraged to… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Danaher Corporation (“Danaher” or “the Company”) (NYSE: DHR). Investors who purchased Danaher securities prior to April 21, 2022, and continue to hold to the present, are encouraged to obtain additional information… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Semler Scientific, Inc. (“Semler” or “the Company”) (NASDAQ: SMLR). Investors who purchased Semler securities prior to March 10, 2021, and continue to hold to the present, are encouraged to obtain additional… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of KinderCare Learning Companies, Inc. (“KinderCare” or “the Company”) (NYSE: KLC). Investors who purchased KinderCare securities prior to October 9, 2024, and continue to hold to the present, are encouraged to obtain… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Charter Communications, Inc. (“Charter” or “the Company”) (NASDAQ: CHTR). Investors who purchased Charter securities prior to July 26, 2024, and continue to hold to the present, are encouraged to obtain additional… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of SelectQuote, Inc. (“SelectQuote” or “the Company”) (NYSE: SLQT). Investors who purchased SelectQuote securities prior to September 9, 2020, and continue to hold to the present, are encouraged to obtain additional information… read more